retatrutide triple agonist Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide: A Triple Agonist Shaping

Results: GLP-1RAs attenuate inflammation by suppressing NF-B and p38 MAPK pathways, reduce oxidative stress, enhance insulin sensitivity, and promote mitochondrial and endothelial stability

Here are the protocols, populations, and published results

A correctly reconstituted solution should be perfectly clear and colorless, like water

Ledesma-Gil G, et al

Weight reduction triggers adaptive changes in hunger and satiety hormones and energy expenditure, which favor weight regain, Neff says

While GLP-1 medications were originally developed to help treat type 2 diabetes, they are now being used as an effective weight management solution for individuals with or without diabetes